Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020197905 - USE OF INOSINE FOR CANCER IMMUNOTHERAPY

Publication Number WO/2020/197905
Publication Date 01.10.2020
International Application No. PCT/US2020/023483
International Filing Date 19.03.2020
IPC
A61K 31/708 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
708having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K 31/522 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/708
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
708having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K 39/39541
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
39541against normal tissues, cells
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Applicants
  • IMMUNOSPARKLE BIOSCIENCE LLC [US]/[US]
Inventors
  • YUAN, Xiangliang
  • HE, Baokun
Agents
  • MIRABEL, Eric, P.
Priority Data
62/822,52422.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF INOSINE FOR CANCER IMMUNOTHERAPY
(FR) UTILISATION DE L'INOSINE EN IMMUNOTHÉRAPIE ANTICANCÉREUSE
Abstract
(EN)
Disclosed are formulations for the treatment of cancer including inosine or a related compound in combination with an immune checkpoint inhibitor including but not limited to immune checkpoint inhibitor binding agents (including anti-CTLA4, anti-PD1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-CD47, anti-VISTA, and anti-PD-L1 ), and optionally also including a reinforcing agent to boost immune response, including CAR-T, CAR-NK, tumor vaccine, oncolytic virus vaccine, TLR7/8 agonist, anti-CD47 or IL-2 receptor agonist and optionally also including other pharmacologically immune-boosting active agents.
(FR)
L'invention concerne des préparations pour le traitement du cancer qui comportent de l'inosine ou un composé associé en combinaison avec un inhibiteur de point de contrôle immunitaire comprenant, mais sans y être limité, des agents se liant à un inhibiteur de point de contrôle immunitaire (comprenant les anti-CTLA4, anti-PD1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-CD47, anti-VISTA et anti-PD-L1), et comprenant éventuellement un agent de renforcement destiné à amplifier la réponse immunitaire, comprenant les agents de type CAR-T, CAR-NK, vaccin antitumoral, vaccin à virus oncolytique, agoniste des TLR7/8, anti-CD47 ou agoniste du récepteur de l'IL-2, et éventuellement comprenant également d'autres agents pharmaceutiquement actifs d'amplification de la réponse immunitaire.
Latest bibliographic data on file with the International Bureau